Cost-effectiveness analysis of metformin versus insulin in the treatment of gestational diabetes mellitus
Archives of Gynecology and Obstetrics · 2024
DOI: 10.1007/s00404-024-07483-5 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Archives of Gynecology and Obstetrics, 2024. Verfasst von Rui Wu und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China. Hauptthemen laut MEDLINE: Metformin, Diabetes, Gestational, Cost-Benefit Analysis, Hypoglycemic Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
OBJECTIVE: Although there have been many studies on gestational diabetes mellitus (GDM) treatment, there is still a knowledge gap regarding the comparative cost-effectiveness of metformin and insulin in the treatment phase. Existing studies have focused on treatment efficacy and drug safety, but relatively little has been explored regarding cost-effectiveness analysis. In particular, no comprehensive study has evaluated the cost-effectiveness of metformin and insulin for GDM treatment. Therefore, this study aimed to fill this knowledge gap by conducting a cost-effectiveness analysis of these two treatments for GDM. METHODS: A decision-analytic model was used to compare the cost-effectiveness of metformin and insulin in China. Probabilities, costs, and utilities were derived from the literature. The cost and quality-adjusted life years (QALYs) were calculated using the roll-back method. The strategy was considered cost-effective if the incremental cost-effectiveness ratio (ICER) was below the willingness-to-pay (WTP) threshold of ¥242,938 per QALY. Sensitivity analyses were also conducted to assess the robustness of the results. RESULTS: The roll-back analysis indicated that insulin was not cost-effective compared to metformin, resulting in increased costs and decreased QALYs, with a negative ICER. These findings suggested that metformin is a cost-effective option than insulin. Furthermore, the sensitivity analysis showed that the model was robust. CONCLUSIONS: Compared with insulin, metformin is a cost-effective treatment option for GDM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, China.
- School of Medical Devices, Shenyang Pharmaceutical University, Shenyang, China. zuojing1006@hotmail.com.
ORCID-Profile: Rui Wu, Zuojing Li
Zitieren
APA
Wu, R., & Li, Z. (2024). Cost-effectiveness analysis of metformin versus insulin in the treatment of gestational diabetes mellitus. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-024-07483-5
Vancouver
Wu R, Li Z. Cost-effectiveness analysis of metformin versus insulin in the treatment of gestational diabetes mellitus. Archives of Gynecology and Obstetrics. 2024. doi:10.1007/s00404-024-07483-5
BibTeX
@article{Wu2024,
author = {Wu, Rui and Li, Zuojing},
title = {Cost-effectiveness analysis of metformin versus insulin in the treatment of gestational diabetes mellitus},
journal = {Archives of Gynecology and Obstetrics},
year = {2024},
doi = {10.1007/s00404-024-07483-5}
}
EUVIMED